Xplore-2 trial information for clinicians online
U.S. clinicians can now learn more about the FDA-approved Xplore-2 clinical trial online. The trial is currently recruiting pediatric patients across several leading centers in the USA.
Xplore-2 is an FDA-approved Early Feasibility Study evaluating Xeltis’ novel restorative pulmonary heart valve for Right Ventricular Outflow Tract (RVOT) reconstruction. Xeltis’ restorative pulmonary valve is an investigational device not approved for use in the United States.
Every year in the USA, approximately 40,000 children are born with congenital heart disease (CHD). Around 15-20 percent of these children have congenital defects of the RVOT. Defective RVOTs require surgical intervention, which often involves replacement of the pulmonary valve.
For more information on the Xplore-2 trial and to access the website please visit xplore2md.com.